Astragaloside in cancer chemoprevention and therapy.
10.1097/CM9.0000000000002661
- Author:
Yaning WANG
1
;
Zhuo ZHANG
2
;
Zhaohua CHENG
1
;
Wei XIE
3
;
Hanjiao QIN
4
;
Jiyao SHENG
1
Author Information
1. Department of Hepatobiliary and Pancreatic Surgery, Second Hospital of Jilin University, Changchun, Jilin 130041, China.
2. Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, Jilin 13033, China.
3. Department of Ophthalmology, Second Hospital of Jilin University, Changchun, Jilin 130041, China.
4. Department of Radiotherapy, Second Hospital of Jilin University, Changchun, Jilin 130041, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Chemoprevention;
Antineoplastic Agents;
Neoplasms/prevention & control*;
Saponins/pharmacology*;
Triterpenes/pharmacology*
- From:
Chinese Medical Journal
2023;136(10):1144-1154
- CountryChina
- Language:English
-
Abstract:
Tumor chemoprevention and treatment are two approaches aimed at improving the survival of patients with cancers. An ideal anti-tumor drug is that which not only kills tumor cells but also alleviates tumor-causing risk factors, such as precancerous lesions, and prevents tumor recurrence. Chinese herbal monomers are considered to be ideal treatment agents due to their multi-target effects. Astragaloside has been shown to possess tumor chemoprevention, direct anti-tumor, and chemotherapeutic drug sensitization effects. In this paper, we review the effects of astragaloside on tumor prevention and treatment and provide directions for further research.
